BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38346605)

  • 1. Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.
    Samia S; Sandeep Chary P; Khan O; Kumar Mehra N
    Int J Pharm; 2024 Mar; 653():123889. PubMed ID: 38346605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.
    Alam M; Alam S; Shamsi A; Adnan M; Elasbali AM; Al-Soud WA; Alreshidi M; Hawsawi YM; Tippana A; Pasupuleti VR; Hassan MI
    Front Oncol; 2022; 12():869672. PubMed ID: 35402265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging ways to treat breast cancer: will promises be met?
    Samadi P; Saki S; Dermani FK; Pourjafar M; Saidijam M
    Cell Oncol (Dordr); 2018 Dec; 41(6):605-621. PubMed ID: 30259416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
    Yu Q; Lan T; Ma Z; Wang Z; Zhang C; Jiang Y; Zhao Z
    Transl Androl Urol; 2023 Aug; 12(8):1296-1307. PubMed ID: 37680227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
    Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.
    Zhang Z; Hou L; Liu D; Luan S; Huang M; Zhao L
    Acta Pharm Sin B; 2024 Jun; 14(6):2378-2401. PubMed ID: 38828138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell lymphoma-2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy.
    Gong Q; Wang H; Zhou M; Zhou L; Wang R; Li Y
    Med Res Rev; 2024 Mar; 44(2):707-737. PubMed ID: 37983840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer.
    Marx D; Meden H
    Methods Mol Med; 2001; 39():687-91. PubMed ID: 21340831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.
    Taylor ST; Hickman JA; Dive C
    J Natl Cancer Inst; 2000 Jan; 92(1):18-23. PubMed ID: 10620629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.
    Ngoi NYL; Choong C; Lee J; Bellot G; Wong ALA; Goh BC; Pervaiz S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32131385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bax mediates the apoptosis-sensitizing effect of maspin.
    Liu J; Yin S; Reddy N; Spencer C; Sheng S
    Cancer Res; 2004 Mar; 64(5):1703-11. PubMed ID: 14996730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
    Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation.
    Schmitt E; Sané AT; Steyaert A; Cimoli G; Bertrand R
    Biochem Cell Biol; 1997; 75(4):301-14. PubMed ID: 9493953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
    Levesley J; Steele L; Brüning-Richardson A; Davison A; Zhou J; Ding C; Lawler S; Short SC
    Neuro Oncol; 2018 Jan; 20(2):203-214. PubMed ID: 29016820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.
    Bargou RC; Daniel PT; Mapara MY; Bommert K; Wagener C; Kallinich B; Royer HD; Dörken B
    Int J Cancer; 1995 Mar; 60(6):854-9. PubMed ID: 7896458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.
    Yao Q; Chen J; Lv Y; Wang T; Zhang J; Fan J; Wang L
    Tumour Biol; 2011 Dec; 32(6):1163-71. PubMed ID: 21861179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
    Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
    BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.